We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Increased Mean Corpuscular Hemoglobin Concentration Scrutinized for Accuracy

By LabMedica International staff writers
Posted on 21 Dec 2016
In daily practice in hematology laboratories, spurious increased mean corpuscular hemoglobin concentration (MCHC) induces an analytical alarm and needs prompt corrective action to ensure delivery of the right results to the clinicians.

Elevated MCHC is a rare event in routine laboratory practice, but it must be managed properly. More...
In daily practice, the MCHC limit defined by a specific commercial analyzer is fixed at 365 g/L. Exceeding this value leads to a suspicious ‘flag’ and this ‘flag’ has to be considered in an accreditation context to assess the accuracy of reported parameters.

Hematologists at the Hôpital de la Conception (Marseille, France) measured and analyzed in parallel with blood smears from 128 unknown patients with MCHC greater than 365 g/L, all erythrocyte parameters including reticulocyte parameters, chemistry index and osmolality. Differences between optical parameters (RBC-O, HGB-O) and usual parameters (RBC, HGB) obtained by impedance and photometry were also reported.

The scientists used the Sysmex XN-10 RET automated hematology system (Sysmex Corporation, Kobe Japan) that has two different technologies for achieving a full erythrocyte analysis. Erythrocytes are counted using an impedance method with a hydrodynamic focusing system in a fixed volume at room temperature. When required, XN-10 RET can provide a second erythrocyte count (RBC-O) using fluorescence flow cytometry after stabilization and warming at 41 °C in the incubation chamber. RBC-O is a measured parameter, corresponding to total erythrocyte count, including reticulocyte counts, whereas HGB-O is a calculated parameter derived mainly from the RBC-O count and RBC hemoglobin content (RBC-He).

The team classified four groups from their observations: 22 with red blood cell (RBC) agglutination; 17 with optical interference; 18 with RBC disease and 71 others including unclassified and/or patients with hyposmolar plasma. The use of RBC-O and HGB-O permitted efficient correction of the abnormalities when RBC agglutination and/or optical interference were present in 36 of 39 patients. Reticulocyte parameters permitted to elaborate an RBC score that allowed a highly sensitive detection of RBC disease patients (17/18).

The authors concluded that in case of elevated MCHC, their study proves the capability of XN-10 RET optical parameters to provide solutions in the majority of cases, especially concerning RBC cold agglutination and optical interference. The calculated RBC score offers a highly useful tool for managing a blood smear and specifying patients with RBC disease. This original study allows optimization of the workflow in laboratories eliminating manual tasks, guiding biological interpretation in the case of elevated MCHC. The study was originally published online on August 27, 2016, in the International Journal of Laboratory Hematology.

Related Links:
Hôpital de la Conception
Sysmex

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AI-powered ctDNA analysis provides clinicians with a new lens to monitor disease evolution (Photo courtesy of Brandon Stelter, Katie Han, Kyle Smith, and Paul Northcott)

AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy

Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Sophie Paczesny, M.D., Ph.D and her team have made BIOPREVENT freely available for researchers and clinician to test and learn from (Photo courtesy of Cliff Rhodes)

AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear

Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.